Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes

DPP-4 Inhibitors—Renoprotection in Diabetic Nephropathy?

(2014) Usha Panchapakesan et al.   DIABETES

Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice

(2014) Muralikrishna Gangadharan Komala et al.   PLoS One

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes

(2013) Ryo Kodera et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats

(2012) R. Preston Mason et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Novel aspects of cellular action of dipeptidyl peptidase IV/CD26

(2011) Siegfried Ansorge et al.   BIOLOGICAL CHEMISTRY

High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV

(2011) C. Marchetti et al.   DIABETOLOGIA

Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study

(2011) Johanna W M Nin et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

(2011) Cristina Mega et al.   Experimental Diabetes Research

Peptidomics of the Prolyl Peptidases

(2010) Anna Mari Lone et al.   AAPS Journal